• McKesson raised fiscal 2027 adjusted diluted EPS guidance to $45.60-$46.40 from $44.20-$45 during its second-quarter earnings call.
• CEO Brian S. Tyler, CFO Kenny K. Cheung and Paula Adkison attended the November 4, 2026, call.
• Quarterly adjusted diluted EPS rose 18% to $11.68; revenue increased 8% to $111 billion.
• The completed $2.25 billion Precision Medicine Group acquisition is expected to contribute $0.10-$0.20 to adjusted diluted EPS.
• A proposed $1.4 billion investment for 49% of Option Care Health is expected to close in the first half of calendar 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. McKesson Corporation published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.